logo
Legionnaires' Outbreak in Harlem Kills 2 and Sickens More Than 50

Legionnaires' Outbreak in Harlem Kills 2 and Sickens More Than 50

Two people have died and more than 50 have been sickened in a fast-growing outbreak of Legionnaires' disease in Central Harlem that has health officials still searching for the source more than a week after people began turning up ill.
Legionnaires' disease is a form of pneumonia caused by the Legionella bacterium, which thrives in warm, stagnant water. In New York City, many of the outbreaks are caused by water vapor spewed from rooftop cooling towers. The bacteria can float along on water vapor for sometimes thousands of feet before someone inhales the pathogen and is sickened, researchers believe.
Most healthy people don't become sick after being exposed to the bacteria. But many people are vulnerable, including older adults, smokers and people with chronic diseases and compromised immune systems.
On average, about 200 to 500 people annually are diagnosed with Legionnaires' disease in New York, and they generally require hospitalization. Just over a dozen die each year.
The disease got its name from a 1976 convention in Philadelphia held by the American Legion, the veterans' organization, that resulted in a huge outbreak of mysterious pneumonia cases. Months later, scientists at the Centers for Disease Control and Prevention revealed the cause: a never-before-identified bacterium, now called Legionella. Scientists quickly realized that it was responsible for tens of thousands of cases of pneumonia each year. The number has only grown.
New York has an especially high rate of cases.
Many cases trace back to mist emanating from cooling towers atop buildings, which play a critical role in cooling systems. Warm water is piped to the rooftop cooling tower, where fans cool the water through evaporation, sending the mist into the environment. If not properly maintained, the cooling towers can become incubators for the Legionella bacteria, which thrive in warm, standing water.
Want all of The Times? Subscribe.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BlinkRx Launches "Operation Access Now" to Accelerate and Scale Direct‑to‑Patient and Direct‑to‑Business Programs
BlinkRx Launches "Operation Access Now" to Accelerate and Scale Direct‑to‑Patient and Direct‑to‑Business Programs

Yahoo

time22 minutes ago

  • Yahoo

BlinkRx Launches "Operation Access Now" to Accelerate and Scale Direct‑to‑Patient and Direct‑to‑Business Programs

Operation Access Now enables pharmaceutical manufacturers to launch direct‑to‑patient programs within 21 days NEW YORK, August 07, 2025--(BUSINESS WIRE)--BlinkRx, the nation's leading prescription lifecycle management platform, today announced the launch of Operation Access Now, a rapid deployment initiative that enables pharmaceutical manufacturers to build and launch direct-to-patient (DTP) and direct‑to‑business (DTB) channels that expand medication access and deliver pricing transparency in as little as 21 days. This program comes at a moment of growing urgency across the life sciences industry. As traditional access models struggle to meet patient and provider expectations, leading brands are turning to faster, more scalable approaches. BlinkRx's national infrastructure already supports millions of patients across all 50 states. The platform's patient-centric design removes every barrier for patients to start and stay on therapy and delivers significant lift for brands: on average, 52% more patient starts and 41% more fills per patient. With Operation Access Now, the initiative enables: Rapid Stand‑Up: DTP programs that can be operational in as little as 21 days, thanks to BlinkRx's turnkey platform and flexible rules engine. Future-Proof: A modular platform that allows pharmaceutical manufacturers to start with a DTP solution and expand into future capabilities as needs and regulations change. For example, the platform can be deployed for DTB models, and can service both cashpay and insurance patients. Scale: Unique automation capabilities that enable pharmaceutical manufacturers to effortlessly scale based on patient demand and adoption. Legacy DTP solutions, such as copay cards and standalone cash pharmacies, are often costly, inefficient, and prone to patient and physician frustration- causing delays in access, misuse, and poor experiences. BlinkRx's platform addresses these ecosystem issues while ensuring strict regulatory compliance. "Operation Access Now is about removing every barrier between manufacturers and the patients who need their therapies," said Geoffrey Chaiken, Co‑Founder and CEO of BlinkRx. "We're prepared to enable manufacturers to deploy DTP programs and deliver the speed, scale, and flexibility the market demands." About BlinkRx BlinkRx is a Prescription Lifecycle Management Platform that allows the most innovative Life Sciences companies to design every aspect of the prescription journey to unlock branded medication affordability and access for all Americans. Learn more at View source version on Contacts For media inquiries, please contact: Press@

Eli Lilly weight loss pill shows promise in latest clinical trial
Eli Lilly weight loss pill shows promise in latest clinical trial

Yahoo

time22 minutes ago

  • Yahoo

Eli Lilly weight loss pill shows promise in latest clinical trial

Eli Lilly, the maker of Zepbound and Mounjaro, said its experimental GLP-1 pill successfully helped adults with obesity lose weight in a Phase 3 trial, as the company moves closer to submitting the drug for approval from the Food and Drug Administration. In a news release Thursday, the drugmaker said the oral medication, called orforglipron, helped adults lose an average of 27.3 pounds in a 72-week trial. The pill showed "significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies," the release added. The results shared by Eli Lilly, which have not been peer reviewed and published as of Thursday morning, are "on par with what we see with the injectable forms of these drugs," Dr. Céline Gounder, CBS News medical contributor and editor-at-large for public health at KFF Health News, said on "CBS Mornings" Thursday. Some investors, however, were disappointed with the results Eli Lilly provided. Shares of the company were down about 13.9% Thursday morning. Also like the injectables, the pill showed some side effects among participants, with the most commonly reported issues being nausea, vomiting, diarrhea and constipation. "About 10% of people who are taking the highest dose, which is also what got you that high level of weight loss ... were unable to continue, had to stop, due to the side effects," Gounder said. Eli Lilly said it is on track to submit orforglipron to regulatory agencies like the FDA for approval later this year, which means it could be available to consumers in 2026, Gounder said. It is unclear how much the drug will cost, but Gounder said she expected it to cost less than injectables. A pill would be a "game changer" in terms of accessibility, she said. "With the injectables, you need needles. You need to be able to refrigerate," she said. "What's great about the pills is it's a lot cheaper to manufacture a pill. It's a lot easier to take, and there are no restrictions around, you have to take it with water, with food. You can take it at any time of day. So this will make it a lot more accessible to people, both in terms of cost as well as convenience." Earlier this year, orforglipron's efficacy and safety was measured in a trial with adults who have Type 2 diabetes, showing positive results. Sneak peek: The Strange Shooting of Alex Pennig Neil deGrasse Tyson weighs in on plans for a moon-based nuclear reactor "Platonic" stars talk about new season and maintaining friendships as adults Solve the daily Crossword

Hillsdale Hospital launches Rural Health Strong to advocate against cuts, changes
Hillsdale Hospital launches Rural Health Strong to advocate against cuts, changes

Yahoo

time22 minutes ago

  • Yahoo

Hillsdale Hospital launches Rural Health Strong to advocate against cuts, changes

Hillsdale Hospital has launched a new campaign, Rural Health Strong, to highlight the significance of rural health services and prompt nationwide action to preserve them, according to a community announcement. It marks the hospital's first new campaign since "Hillsdale Strong. Hillsdale First." — which encouraged the community to utilize local health services. The new campaign was developed in response to Medicaid cuts introduced by the One Big Beautiful Bill Act, along with other regulatory changes and program cancellations that are already affecting rural hospitals, according to the announcement. 'We have to come together and lift our voices,' President and CEO Jeremiah J. Hodshire wrote in the announcement. 'We're financially viable right now, and to sustain that over time, we must be Rural Health Strong. Now is a critical time for us to support and advocate for all rural hospitals — our brothers and sisters around the country.' Rural Health Strong is designed to raise awareness of the value rural hospitals bring to their communities and share the stories of those most affected by legislation that disadvantages them, according to the announcement. 'We encourage anyone touched by rural health to submit photos of what rural health means to them and stories of how rural health has impacted their lives,' wrote Communications and Donor Development Manager Kyrsten Newlon. More: New spinal navigation tech enhances surgeries at Hillsdale Hospital Photos and stories can be sent to marketing@ or submitted at Learn more at This story was created by Janis Reeser, jreeser@ with the assistance of Artificial Intelligence (AI). Journalists were involved in every step of the information gathering, review, editing and publishing process. Learn more at This article originally appeared on Hillsdale Daily News: Hillsdale Hospital launches Rural Health Strong Campaign Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store